Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Array BioPharma Inc.

Division of Array Biopharma Inc.
www.arraybiopharma.com

Latest From Array BioPharma Inc.

Pipeline Watch: Phase III Progress With Nimotuzumab, Solriamfetol, And Upadacitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Approvals Research & Development

Will Pierre Fabre and Array Have Best-In-Class MEK/BRAF Inhibitor?

Updated results from the COLUMBUS trial in BRAF-mutant advanced melanoma presented at ASCO revealed stellar overall survival data for the combination of encorafenib and binimetinib. Rivals Novartis and Roche will have noted that approval in the US is expected before the end of June.

Cancer Clinical Trials

Novartis' Growth Driver Tafinlar/Mekinist Picks Up New Melanoma, Thyroid Indications

New FDA labeling brings Tafinlar/Mekinist into adjuvant melanoma setting, but Bristol's competing Opdivo already has captured nearly 50% of the market and is approved regardless of genetic mutation.

Approvals Clinical Trials

Pipeline Watch: Phase III Progress With Eylea, Tecentriq And HTX-011

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Array Biopharma Inc.
  • Senior Management
  • Ron Squarer, CEO
    Jason Haddock, CFO
    Andrew Robbins, COO
    Nicholas A Saccomano, PhD, CSO
    Victor Sandor, MD, CMO
  • Contact Info
  • Array BioPharma Inc.
    Phone: (303) 381-6600
    3200 Walnut St.
    Boulder, CO 80301
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register